#USA #Halifax #Precision BioLogic #George King Bio-Medical #Affinity Biologicals

Revolutionizing Hemostasis Diagnostics

In a groundbreaking effort to enhance hemostasis diagnostics, Precision BioLogic Inc., a frontrunner in the field, is making a substantial mark through strategic collaborations with its subsidiaries, Affinity Biologicals and George King Bio-Medical. This innovation-driven approach is garnering significant attention from clinicians and researchers focused on bleeding disorders around the world.

Ever since the announcement of the expanded functionality of the CRYOcheck™ Chromogenic Factor VIII assay, which is designed to address emerging hemophilia treatments like Mim8 (a next-generation bispecific antibody targeting hemophilia A), Precision BioLogic has experienced an uptick in interest and inquiries within the scientific community. Notably, in light of Nova Nordisk's submission of Mim8 to the U.S. FDA, the demand for reliable and precise diagnostic tools has never been more pressing.

Paul Empey, President and CEO of Precision BioLogic, noted the increase in inquiries during their exhibition at the International Society on Thrombosis and Haemostasis (ISTH) 2026 in Paris. He stated, “We received numerous questions concerning our bovine Chromogenic Factor VIII and its capabilities in accurately measuring factor VIII levels, especially in the context of newer FVIII replacement products as well as bispecific antibodies.” This growing recognition emphasizes the essential role of chromogenic assays in coagulation laboratories, where reliable measurements can potentially save lives and enhance treatment outcomes.

The research prowess of Precision BioLogic was also showcased at the ISTH event, highlighted by the presentation of two scientific posters:

• - An Automated Lupus Anticoagulant Assay Resistant to Anticoagulant Drugs Including DOACs and Oral FXI Inhibitors.
• - Impact of Heat-Stable Factor VIII Mimetics and Replacement Therapies on Inhibitor Titer Using a Modified Nijmegen-Bethesda Test Across Bovine Chromogenic FVIII Assays.

Following their successful presence at ISTH, the Precision BioLogic team ventured to the American Association for Clinical Chemistry (ADLM) conference in Anaheim, CA. They emphasized Affinity Biologicals' advanced manufacturing capabilities, positioning them as a key player in the production of diagnostic solutions. Furthermore, their attendance at the NBDF's Bleeding Disorders Conference in Orlando, FL provided a platform for interaction with various stakeholders in the bleeding disorders community. Discussions focused on the critical role of plasma donation in facilitating research and advancing diagnostic and treatment methodologies.

As summer 2026 comes to a close, the collaborative efforts of Precision BioLogic, Affinity Biologicals, and George King Bio-Medical are set to redefine the landscape of hemostasis research and diagnostics. With an unwavering commitment to delivering reliable products, responsive services, and meaningful innovations, these organizations are strategically positioned to meet burgeoning needs in the global hemostasis community.

About Precision BioLogic

Precision BioLogic Inc. is dedicated to pioneering advancements in hemostasis diagnostics through its CRYOcheck™ line of frozen products, widely utilized by healthcare professionals globally for diagnosing coagulation disorders. The organization has strengthened its market position through strategic acquisitions, including Affinity Biologicals in November 2018 and George King Bio-Medical in October 2025. Together, these entities are set on a mission to elevate hemostasis diagnostics and research, ensuring that healthcare providers have access to state-of-the-art products and solutions.

For further information, visit www.precisionbiologic.com or reach out to Elaine Benoit at [email protected], 902.430.7795.